Investigation of paclitaxel-carboplatin one-cycle neoadjuvant chemotherapy plus trastuzumab in HER2-positive breast cancer

Objective: This study aims to observe the curative effects and safety of paclitaxel-carboplatin one-cycle neoadjuvant chemotherapy plus trastuzumab on HER2-positive breast cancer. Materials and Methods: Forty-two patients with HER2-positive breast cancer were included into this study. These patients underwent paclitaxel-carboplatin one-cycle neoadjuvant chemotherapy plus trastuzumab therapy for four courses of treatment. Paclitaxel (80 mg/m² ) and carboplatin (AUC 1.5) were administered via i.v. g.t.t., d1, repeated every week. Three weeks was considered as one course of treatment, and there were 12 weeks in total. At the same time, trastuzumab (Herceptin) one-cycle therapy was combined. Its efficacy and adverse reactions were evaluated, and the major observational indicator was pathological complete remission (pCR). Results: A total of 41 patients successfully underwent paclitaxel-carboplatin one-cycle neoadjuvant chemotherapy plus trastuzumab therapy for four courses of treatment, and the total clinical effective rate was 97.6%. Clinical complete remission (CR) was achieved by 25 patients (59.5%), partial remission (PR) of the tumor was achieved by 16 patients (38.1%), and pCR was achieved by 23 patients (54.8%). Adverse reactions included bone marrow suppression and hair loss, and no toxic and adverse reactions of the heart were observed. Conclusion: In the neoadjuvant chemotherapy of HER-2-positive breast cancer, paclitaxelcarboplatin one-cycle neoadjuvant chemotherapy plus trastuzumab therapy for four courses of treatment achieved better efficacy and tolerance.

Paclitaxel plus CarboPlatin; Trastuzumab; Breast cancer; Neoadjuvant Therapy; HER2.

[1] Mauri D., Pavlidis N., Ioannidis J.P.: “Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis”. J. Natl. Cancer Inst., 2005, 7, 188.

[2] Lobbes M.B., Prevos R., Smidt M., Tjan-Heijnen V.C.G., van- Goethem M., Schipper R., et al.: “The role of mag-netic resonance imaging in assessing residual diseaseand pathologic complete response in breast cancer pabents receiving neoadjuvant chemotherapy: a systematicreview”. Insights Imaging, 2013, 4, 163.

[3] Marinovich M.L., Houssami N., Macaskill P., Sardanelli F., Irwig L., Mamounas E.P., et al.: “Metes-a-nalysis of magnetic resonance imaging in detecting residual breast cancer after neoadjuvant therapy”. J. Natl. Cancer Inst., 2013, 105, 321.

[4] van der Hage J.A., van de Velde C.J., Julien J.P., Tubiana-Hulin M., Vandervelden C., Duchateau L.: “Preoperative chemotherapy in primary operable breast cancer Results from the European Organi zation for Research and Treatment of Cancer trial 10902”. J. Clin. Oncol., 2001, 19, 4224.

[5] Luangdilok S., Samarnthai N., Korphaisarn K.: “Association between pathological complete response and outcome following neoadjuvant chemotherapy in locally advanced breast cancer patients”. J. Breast Cancer, 2014, 17, 376.

[6] Kaufmann M., von Minckwitz G., Mamounas E.P., Cameron D., Carey L.A., Cristofanilli M., et al.: “Recommendations from an international consensus conference on the current status and future of neoadjuvant systemictherapy in primary breast cancer”. Ann. Surg. Oncol., 2012, 19, 1508.

[7] Valachis A., Mauri D., Polyzos N.P., Chlouverakis G., Mavroudis D., Georgoulias V.: “Trastuzumab combined to neoadjuvant chemotherapy in patients with HER2-positive breast cancer: a systematic review and meta-analysis”. Breast, 2011, 20, 485.

[8] Yardley D.A., Tripathy D., Brufsky A.M., Rugo H.S., Kaufman P.A., Mayer M., et al.: “Long-term survivor characteristics in HER2- positive metastatic breast cancer from regist HER”. Br. J. Cancer, 2014, 110, 2756.

[9] Babar T., Blomberg C., Hoffner E., Yan X.: “Anti-HER2 cancer therapy and cardiotoxicity”. Curr. Pharm. Des., 2014, 20, 4911.

[10] Aitelhaj M., Lkhouyaali S., Rais G., Mohtaram A., Raissouni S., Ghissassi B., et al.: “Cardiac safety of the adjuvant Trastuzumab in a Moroccan population: observational monocentric study of about 100 patients”. BMC Res Notes, 2013, 6, 339.

[11] Perez E.A., Suman V.J., Davidson N.E., Martino S., Kaufman P.A., Lingle W.L., et al.: “HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial”. J. Clin. Oncol., 2006, 24, 3032.

[12] Buzdar A.U., Ibrahim N.K., Francis D., Booser D.J., Thomas E.S., Theriault R.L., et al.: “Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer”. J. Clin. Oncol., 2005, 23, 3676.

[13] Untch M., Rezai M., Loibl S., Fasching P.A., Huober J., Tesch H., et al.: “Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study”. J. Clin. Oncol., 2010, 28, 2024.

[14] Valachis A., Mauri D., Polyzos N.P., Chlouverakis G., Mavroudis D., Georgoulias V.: “Trastuzumab combined to neoadjuvant chemotherapy in patients with HER2 positive breast cancer;A systematic review and meta analysis”. Breast, 2011, 20, 488.

[15] Pegram M.D., Konecny G.E., O’Callaghan C., Beryt M., Pietras R., Slamon D.J.: “Rational combinations of trastuzuumab with chemotherapeutic drugs used in the treatment of breast cancer”. J. Natl. Cancer Inst., 2004, 96, 739.

[16] Farolfi A., Melegari E., Aquilina M., Scarpi E., Ibrahim T., Maltoni R., et al.: “Trastuzumab-induced cardiotoxicity in early breast cancer patients: a retrospective study of possible risk and protective factors”. Heart, 2013, 99, 634.

[17] Erin J., Bowles A., Wellman R.: “Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study”. Oxford J., 2012, 104, 1293.

[18] Milano G.A., Serres E., Ferrero J.M., Ciccolini J.: “Trastuzumab-induced cardiotoxicity:is it a personalized risk?” Curr. Drug Targets, 2014, 15, 1200.

[19] Marinko T., Dolenc J., Bilban-Jakopin C.: “Cardiotoxicity of concomitant radiotherapy and trastuzumab for early breast cancer”. Radiol. Oncol., 2014, 48, 105.

[20] Lu C.Y., Srasuebkul P., Drew A.K., Chen K., Ward R.L., Pearson S.A.: “Trastuzumab therapy in Australia: which patients with HER2+ metastatic breast cancer are assessed for cardiac function”. Breast, 2013, 22, 482.

[21] Gianni L., Eiermann W., Semiglazov V., Lluch A., Tjulandin S., Zambetti M., et al.: “Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort”. Lancet Oncol., 2014, 15, 640.